JP7020909B2 - 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法 - Google Patents

抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法 Download PDF

Info

Publication number
JP7020909B2
JP7020909B2 JP2017504058A JP2017504058A JP7020909B2 JP 7020909 B2 JP7020909 B2 JP 7020909B2 JP 2017504058 A JP2017504058 A JP 2017504058A JP 2017504058 A JP2017504058 A JP 2017504058A JP 7020909 B2 JP7020909 B2 JP 7020909B2
Authority
JP
Japan
Prior art keywords
antibody
multispecific
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017504058A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523176A5 (https=
JP2017523176A (ja
Inventor
アレン アービング ブライアン
リン ラ ポート シェリー
ゲイリー サガート ジェイソン
ロバート ホステッター ダニエル
ジェニファー ラゾ オリビア
ホワイト クレイトン
ホープ リチャードソン ジェニファー
Original Assignee
シトムクス セラピューティクス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53765629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7020909(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by シトムクス セラピューティクス，インコーポレイティド filed Critical シトムクス セラピューティクス，インコーポレイティド
Publication of JP2017523176A publication Critical patent/JP2017523176A/ja
Publication of JP2017523176A5 publication Critical patent/JP2017523176A5/ja
Application granted granted Critical
Publication of JP7020909B2 publication Critical patent/JP7020909B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017504058A 2014-07-25 2015-07-24 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法 Active JP7020909B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462029325P 2014-07-25 2014-07-25
US62/029,325 2014-07-25
PCT/US2015/042053 WO2016014974A2 (en) 2014-07-25 2015-07-24 Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021012481A Division JP7168702B2 (ja) 2014-07-25 2021-01-28 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法

Publications (3)

Publication Number Publication Date
JP2017523176A JP2017523176A (ja) 2017-08-17
JP2017523176A5 JP2017523176A5 (https=) 2018-09-06
JP7020909B2 true JP7020909B2 (ja) 2022-02-16

Family

ID=53765629

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017504058A Active JP7020909B2 (ja) 2014-07-25 2015-07-24 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
JP2021012481A Active JP7168702B2 (ja) 2014-07-25 2021-01-28 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
JP2022171196A Active JP7564853B2 (ja) 2014-07-25 2022-10-26 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
JP2024168603A Pending JP2025000814A (ja) 2014-07-25 2024-09-27 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021012481A Active JP7168702B2 (ja) 2014-07-25 2021-01-28 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
JP2022171196A Active JP7564853B2 (ja) 2014-07-25 2022-10-26 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
JP2024168603A Pending JP2025000814A (ja) 2014-07-25 2024-09-27 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法

Country Status (8)

Country Link
US (3) US10669337B2 (https=)
EP (1) EP3172235A2 (https=)
JP (4) JP7020909B2 (https=)
CN (1) CN107108738A (https=)
AU (2) AU2015292406B2 (https=)
BR (1) BR112017001579A2 (https=)
CA (1) CA2955947A1 (https=)
WO (1) WO2016014974A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12060654B2 (en) 2016-11-28 2024-08-13 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
US12077577B2 (en) 2018-05-30 2024-09-03 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising aggrecan binding domain and carrying moiety
US12195528B2 (en) 2017-11-28 2025-01-14 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand-binding activity

Families Citing this family (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
EP2892924B1 (en) * 2012-06-14 2020-11-25 Therapix Biosciences Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
CN105283201B (zh) 2013-03-14 2019-08-02 斯克利普斯研究所 靶向剂抗体偶联物及其用途
CN105722859B (zh) * 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
CA2925106C (en) 2013-09-25 2023-11-14 Cytomx Therapeutics, Inc. Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
UA129760C2 (uk) 2013-12-17 2025-07-30 Дженентек, Інк. Анти-cd3 антитіло та спосіб його застосування
IL270562B (en) 2014-01-31 2022-08-01 Cytomx Therapeutics Inc Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses
JP7020909B2 (ja) 2014-07-25 2022-02-16 シトムクス セラピューティクス，インコーポレイティド 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
SI3221357T1 (sl) 2014-11-20 2020-09-30 F. Hoffmann-La Roche Ag Pogoste lahke verige in načini uporabe
RS61010B1 (sr) 2014-11-20 2020-11-30 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
MA41374A (fr) * 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
WO2016182064A1 (ja) * 2015-05-13 2016-11-17 中外製薬株式会社 多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
EA201792573A1 (ru) 2015-05-21 2018-04-30 Харпун Терапьютикс, Инк. Триспецифические связанные белки и способы их применения
CN114591433A (zh) * 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
EP3352760B1 (en) * 2015-09-21 2026-03-11 Aptevo Research and Development LLC Cd3 binding polypeptides
US11851488B2 (en) * 2015-11-03 2023-12-26 Ambrx, Inc. Anti-CD3-folate conjugates and their uses
ES2873846T5 (en) 2015-11-19 2025-06-23 Revitope Ltd Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
EP4026848A1 (en) 2015-12-09 2022-07-13 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing the cytokine release syndrome
AU2017213886B2 (en) 2016-02-04 2024-03-07 The California Institute For Biomedical Research Humanized anti-CD3 antibodies, conjugates and uses thereof
WO2017143259A1 (en) * 2016-02-19 2017-08-24 Dignity Health Antibody fusion protein and related compositions for targeting cancer
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
CR20180453A (es) * 2016-03-22 2018-12-05 Hoffmann La Roche Moleculas biespecíficas de células t activadas por proteasas
HRP20230528T1 (hr) * 2016-03-22 2023-08-04 F. Hoffmann - La Roche Ag Bispecifične molekule t stanica aktivirane proteazom
CN109476741B (zh) 2016-03-25 2023-02-24 拜奥穆尼克斯制药 与cd38和pd-l1结合的分子
CN109563166B (zh) 2016-04-28 2022-12-20 拜奥穆尼克斯制药 靶向egfr和her2的双特异性抗体
JP7101621B2 (ja) 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． 単一ドメイン血清アルブミン結合タンパク質
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
TW201902512A (zh) 2016-06-02 2019-01-16 瑞士商赫孚孟拉羅股份公司 治療方法
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US11617799B2 (en) 2016-06-27 2023-04-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
KR102726248B1 (ko) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
FI4050034T3 (fi) 2016-09-14 2024-06-10 Teneoone Inc Cd3:een sitoutuvia vasta-aineita
CN106632681B (zh) 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用
MX2019004775A (es) * 2016-11-03 2019-08-05 Squibb Bristol Myers Co Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos.
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
TWI797097B (zh) 2016-11-28 2023-04-01 日商中外製藥股份有限公司 包含抗原結合域與運送部分的多胜肽
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
EP3555620A1 (en) 2016-12-13 2019-10-23 H. Hoffnabb-La Roche Ag Method to determine the presence of a target antigen in a tumor sample
NZ754713A (en) 2016-12-21 2025-11-28 Teneobio Inc Anti-bcma heavy chain-only antibodies
MA47613A (fr) * 2017-02-22 2020-01-01 Aleta Biotherapeutics Inc Compositions et procédés de traitement du cancer
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
CN120842423A (zh) 2017-03-27 2025-10-28 拜奥穆尼克斯制药 稳定的多特异性抗体
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
AU2018250641B2 (en) 2017-04-11 2025-03-13 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
JP7247110B2 (ja) * 2017-06-05 2023-03-28 ヌマブ セラピューティクス アクチェンゲゼルシャフト 新規抗ｃｄ３抗体
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
IL271194B2 (en) 2017-06-20 2024-10-01 Teneobio Inc Anti-bcma heavy chain-only antibodies
US11427642B2 (en) 2017-06-20 2022-08-30 Teneoone, Inc. Anti-BCMA heavy chain-only antibodies
EP3645050A4 (en) * 2017-06-25 2021-08-11 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
JP2020530554A (ja) * 2017-07-20 2020-10-22 シートムエックス セラピューティクス，インコーポレイテッド 活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
CN110799538B (zh) * 2017-08-28 2023-08-01 西雅图免疫公司 抗cd3抗体及其制备和使用方法
KR102678252B1 (ko) * 2017-09-01 2024-06-26 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 재조합 이중특이적 항체
IL302613B2 (en) 2017-09-08 2025-04-01 Maverick Therapeutics Inc Binding proteins are activated under limited conditions
HRP20241268T1 (hr) 2017-10-13 2024-12-06 Harpoon Therapeutics, Inc. Trispecifični proteini i postupci primjene
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CA3287794A1 (en) * 2017-10-14 2025-10-27 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
CN111836828B (zh) 2017-11-28 2024-12-20 中外制药株式会社 包括抗原结合结构域和运送部分的多肽
WO2019126756A1 (en) 2017-12-22 2019-06-27 Teneobio, Inc. Heavy chain antibodies binding to cd22
CN107880129B (zh) * 2017-12-28 2021-01-15 广州市鲁诚生物科技有限公司 一种重组抗体及其制备方法
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2019148445A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
SG11202007572VA (en) * 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
JP2021518603A (ja) 2018-03-20 2021-08-02 シートムエックス セラピューティクス，インコーポレイテッド 哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法
CN110305217B (zh) * 2018-03-27 2022-03-29 广州爱思迈生物医药科技有限公司 双特异性抗体及其应用
BR112020020604A2 (pt) 2018-04-11 2021-01-12 Inhibrx, Inc. Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados
TW202014436A (zh) 2018-05-02 2020-04-16 美商Ｃｙｔｏｍｘ生物製藥公司 抗體、可活化之抗體、雙特異性抗體、及雙特異性可活化之抗體及使用彼之方法
CA3100005A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
US12534734B2 (en) * 2018-05-15 2026-01-27 Drive Therapeutics Llc Stem-loop compositions and methods for inhibiting interleukin-8
SI3797121T1 (sl) * 2018-05-23 2024-09-30 Pfizer Inc. Protitelesa, specifična za CD3, in njihova uporaba
WO2019230868A1 (ja) 2018-05-30 2019-12-05 中外製薬株式会社 単ドメイン抗体含有リガンド結合分子
US12168691B2 (en) 2018-05-31 2024-12-17 Board Of Regents, The University Of Texas System VHS format bi-specific antibodies specific for HER2 and VEGF and use thereof
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
IL279399B1 (en) * 2018-06-14 2026-04-01 Bioatla Llc Multispecific antibody templates
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
TW202016144A (zh) 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
WO2020023553A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
MA53333A (fr) 2018-07-31 2021-11-03 Amgen Inc Formulations pharmaceutiques d'anticorps masqués
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
SG11202103022WA (en) 2018-09-25 2021-04-29 Harpoon Therapeutics Inc Dll3 binding proteins and methods of use
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3864045A2 (en) 2018-10-11 2021-08-18 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
WO2020076992A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. 5t4 single domain antibodies and therapeutic compositions thereof
CA3115082A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
WO2020077257A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
CA3119390A1 (en) 2018-11-12 2020-05-22 Debiopharm International S.A. Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
MY205459A (en) 2018-12-06 2024-10-22 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
CA3131036A1 (en) * 2019-02-22 2020-08-27 Wuhan Yzy Biopharma Co., Ltd. Cd3 antigen-binding fragment and application thereof
WO2020181140A1 (en) 2019-03-05 2020-09-10 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
JP7776987B2 (ja) 2019-04-05 2025-11-27 テネオバイオ， インコーポレイテッド Ｐｓｍａに結合する重鎖抗体
EP3966250A4 (en) * 2019-05-07 2022-11-23 Immunorizon Ltd. PRECURSOR TRI-SPECIFIC ANTIBODY CONSTRUCTIONS AND METHODS OF USE THEREOF
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas
JPWO2020246563A1 (https=) 2019-06-05 2020-12-10
CN114423499A (zh) * 2019-06-06 2022-04-29 佳努克斯治疗公司 与肿瘤激活的t细胞衔接子相关的组合物和方法
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
US20230121775A1 (en) * 2019-06-26 2023-04-20 Amunix Pharmaceuticals, Inc. Cd3 antigen binding fragments and compositions comprising same
WO2021006199A1 (ja) 2019-07-05 2021-01-14 小野薬品工業株式会社 Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
GB201912681D0 (en) * 2019-09-04 2019-10-16 Eth Zuerich Bispecific binding agent that binds to cd117/c-kit and cd3
CN114786776B (zh) 2019-09-18 2026-03-24 拉姆卡普生物阿尔法股份公司 针对ceacam5和cd3的双特异性抗体
EP4034171A1 (en) * 2019-09-23 2022-08-03 Cytomx Therapeutics Inc. Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
CN114502203B (zh) * 2019-11-06 2024-07-19 成都百利多特生物药业有限责任公司 制导和导航控制蛋白及其制备和使用方法
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
EP4090686A4 (en) * 2020-01-17 2024-03-27 Immune Targeting Inc. PRO-ANTIBODY REDUCING OFF-TARGET TOXICITY
CN115380047A (zh) 2020-01-29 2022-11-22 印希比股份有限公司 Cd28单结构域抗体及其多价和多特异性构建体
TWI888487B (zh) * 2020-02-14 2025-07-01 日商協和麒麟股份有限公司 與ｃｄ３結合之雙特異性抗體
WO2021178253A1 (en) * 2020-03-03 2021-09-10 Systimmune, Inc. Anti-cd19 antibodies and methods of using and making thereof
TWI874613B (zh) * 2020-03-17 2025-03-01 美商西雅圖免疫公司 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
JP2024518539A (ja) * 2020-04-04 2024-05-01 ジャナックス セラピューティクス，インク． 抗体を標的とする腫瘍によって活性化されるｅｇｆｒおよびエフェクター細胞抗原に関する組成物および方法
BR112022019841A2 (pt) 2020-04-09 2022-12-06 Cytomx Therapeutics Inc Composições contendo anticorpos ativáveis
AU2021263448B2 (en) 2020-04-29 2026-02-05 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
CN116096754A (zh) * 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法
WO2022035866A1 (en) 2020-08-11 2022-02-17 Janux Therapeutics, Inc. Cleavable linker compositions and methods
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
WO2022046658A1 (en) * 2020-08-24 2022-03-03 Janux Therapeutics, Inc. Antibodies targeting trop2 and cd3 and uses thereof
US12195524B2 (en) 2020-08-25 2025-01-14 Gilead Sciences, Inc. Multi-specific antigen binding molecules targeting HIV and methods of use
US12116411B2 (en) * 2020-11-03 2024-10-15 Abzyme Therapeutics Llc Antibodies binding to human CD3 at acidic pH
CA3196539A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
AU2021374594B2 (en) 2020-11-04 2026-03-05 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
KR20230100732A (ko) 2020-11-04 2023-07-05 제넨테크, 인크. 항-cd20/항-cd3 이중특이성 항체의 피하 투여
KR20230107305A (ko) * 2020-11-10 2023-07-14 상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 클라우딘 18a2 및 cd3에 대한 이중특이성 항체 및 이중특이성 항체의 용도
WO2022115865A2 (en) * 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
EP4259177A4 (en) * 2020-12-08 2024-11-06 Janux Therapeutics, Inc. Peptide compositions and methods for anti-cd3 binding domains
AU2021396172A1 (en) 2020-12-09 2023-07-06 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
EP4274617A4 (en) * 2021-01-05 2025-04-02 Musc Foundation for Research Development A BISPECIFIC AGR2XCD3 ENGAGER FOR THE TREATMENT OF CANCER
WO2022170619A1 (en) * 2021-02-11 2022-08-18 Adagene Pte. Ltd. Anti-cd3 antibodies and methods of use thereof
KR102671734B1 (ko) * 2021-04-13 2024-06-04 건국대학교 글로컬산학협력단 개과 동물의 CD3ε 특이적 항체 또는 그의 항원 결합 단편
MX2023012699A (es) 2021-04-30 2023-11-21 Hoffmann La Roche Dosificacion para el tratamiento con anticuerpo biespecifico anti-cd20/anti-cd3.
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
US12291575B2 (en) 2021-05-14 2025-05-06 Genentech, Inc. Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
WO2022266341A1 (en) * 2021-06-16 2022-12-22 Regents Of The University Of Minnesota Targeted adam17 blocker compounds, anti-adam17 antibodies, methods of making, and methods of using
EP4359443A4 (en) * 2021-06-25 2026-02-25 Harpoon Therapeutics Inc Sustained-release immune cell contact proteins and processing methods
CN117940459A (zh) * 2021-08-25 2024-04-26 西雅图免疫公司 靶向egfr和her3的双特异性四价抗体
WO2023051727A1 (zh) * 2021-09-30 2023-04-06 上海君实生物医药科技股份有限公司 结合cd3的抗体及其用途
AU2022367525A1 (en) 2021-10-15 2024-05-02 Amgen Inc. Activatable polypeptide complex
WO2023064955A1 (en) 2021-10-15 2023-04-20 Cytomx Therapeutics, Inc. Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
JP2024539650A (ja) 2021-10-15 2024-10-29 シートムエックス セラピューティクス，インコーポレイテッド 活性化可能なポリペプチド複合体
IL312728A (en) 2021-11-30 2024-07-01 Daiichi Sankyo Co Ltd Protease-cleavable masked antibodies
CN118401555A (zh) * 2021-12-09 2024-07-26 信华生物药业(广州)有限公司 抗体掩蔽物及其用途
US12269887B2 (en) 2022-01-20 2025-04-08 Regents Of The University Of Minnesota Anti-canine CD16 polypeptides, anti-canine CD64 polypeptides, compositions including same, and methods of using
US20250170255A1 (en) 2022-02-09 2025-05-29 Daiichi Sankyo Company, Limited Environmentally-responsive masked antibody and use thereof
WO2023161853A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
CN119110809A (zh) 2022-02-23 2024-12-10 Xencor股份有限公司 抗CD28 x抗PSMA抗体
WO2023180353A1 (en) 2022-03-23 2023-09-28 F. Hoffmann-La Roche Ag Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
WO2023183888A1 (en) 2022-03-23 2023-09-28 Cytomx Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
US20250333487A1 (en) 2022-03-25 2025-10-30 Cytomx Therapeutics, Inc. Activatable dual-anchored masked molecules and methods of use thereof
WO2023192973A1 (en) 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
JP2025511187A (ja) 2022-04-01 2025-04-15 サイトムエックス セラピューティクス，インク． Ｃｄ３結合タンパク質及びその使用方法
CN119013300A (zh) 2022-04-13 2024-11-22 豪夫迈·罗氏有限公司 抗cd20/抗cd3双特异性抗体的药物组合物和使用方法
US20230406927A1 (en) * 2022-04-29 2023-12-21 Regents Of The University Of Minnesota Masked single-domain antibodies and methods thereof
JP2025525879A (ja) 2022-08-01 2025-08-07 サイトムエックス セラピューティクス，インク． プロテアーゼ切断性基質及びその使用方法
JP2025525868A (ja) 2022-08-01 2025-08-07 サイトムエックス セラピューティクス，インク． プロテアーゼ切断性部分及びその使用方法
TW202424183A (zh) 2022-08-01 2024-06-16 美商Ｃｙｔｏｍｘ生物製藥公司 蛋白酶可切割受質及其使用方法
AR130079A1 (es) 2022-08-01 2024-10-30 Cytomx Therapeutics Inc Restos escindibles por proteasas, y métodos de uso de los mismos
US20260042849A1 (en) 2022-08-01 2026-02-12 Cytomx Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
GB202214132D0 (en) * 2022-09-27 2022-11-09 Coding Bio Ltd CLL1 binding molecules
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
WO2024102723A2 (en) * 2022-11-10 2024-05-16 Janux Therapeutics, Inc. Antibodies targeting egfr and cd3 and uses thereof
US20240417436A1 (en) 2023-01-11 2024-12-19 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
WO2024150175A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
EP4695281A1 (en) 2023-04-12 2026-02-18 CytomX Therapeutics, Inc. Masking polypeptides, activatable cytokine constructs, and related compositions and methods
WO2024216170A2 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
WO2024216146A1 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Masking polypeptides, activatable cytokine constructs, and related compositions and methods
CN121219014A (zh) 2023-04-17 2025-12-26 西纳福克斯股份有限公司 可切割的免疫细胞接合器
WO2024243093A2 (en) * 2023-05-19 2024-11-28 The Regents Of The University Of California Multispecific antibodies targeting cd3 and cd22
WO2025038668A1 (en) 2023-08-14 2025-02-20 Voro Therapeutics, Inc. Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
WO2025077737A1 (en) * 2023-10-11 2025-04-17 Biomap (Suzhou) Intelligent Technology Limited An anti-cd3 activable antibody and the use thereof
WO2025201240A1 (en) * 2024-03-25 2025-10-02 Tavotek Biotherapeutics (Hong Kong) Limited Antibodies targeting cd3, cd28, and pd-l1 and uses thereof
WO2025230233A1 (ko) * 2024-05-03 2025-11-06 국민대학교산학협력단 인간 cd3에 특이적인 항체 및 이의 용도
WO2025235515A1 (en) 2024-05-07 2025-11-13 Cytomx Therapeutics, Inc. Activatable polypeptide complex formulations
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods
WO2026006492A2 (en) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anti-prame/hla-a2 antibodies and uses thereof
WO2026006495A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof
WO2026020161A1 (en) 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods
WO2026024841A1 (en) 2024-07-24 2026-01-29 Astellas Us Llc Bispecific antibodies that bind cd3 and muc1 and methods of use thereof
WO2026035650A2 (en) 2024-08-05 2026-02-12 Cytomx Therapeutics, Inc. Cleavable polypeptides and methods of use thereof
WO2026052652A1 (en) * 2024-09-03 2026-03-12 F. Hoffmann-La Roche Ag Cytokine receptor agonist
WO2026052654A1 (en) * 2024-09-03 2026-03-12 F. Hoffmann-La Roche Ag Cytokine receptor agonist

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009511521A (ja) 2005-10-11 2009-03-19 ミクロメット・アクチェンゲゼルシャフト 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
JP2010524435A (ja) 2007-04-03 2010-07-22 マイクロメット アーゲー 種間特異的二重特異性バインダー
JP2012504403A (ja) 2008-10-01 2012-02-23 マイクロメット アーゲー 異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体
JP2012514982A (ja) 2009-01-12 2012-07-05 サイトムエックス セラピューティクス，エルエルシー 改変した抗体組成物、それを作製および使用する方法
WO2013128194A1 (en) 2012-02-28 2013-09-06 The University Of Birmingham Immunotherapeutic molecules and uses
WO2013192546A1 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
WO2014047231A1 (en) 2012-09-21 2014-03-27 Regeneron Pharmaceuticals, Inc. Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3788058T2 (de) 1986-08-28 1994-04-21 Teijin Ltd Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
WO1991001752A1 (en) 1989-07-27 1991-02-21 Fred Hutchinson Cancer Research Center Immunosuppressive monoclonal antibodies, hybridomas and methods of transplantation
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
US5968509A (en) 1990-10-05 1999-10-19 Btp International Limited Antibodies with binding affinity for the CD3 antigen
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
IT1271461B (it) 1993-12-01 1997-05-28 Menarini Ricerche Sud Spa Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
CZ302070B6 (cs) 1998-04-21 2010-09-29 Micromet Ag Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
WO2001091798A2 (en) 2000-06-01 2001-12-06 Universite Catholique De Louvain Tumor activated prodrug compounds
ATE513563T1 (de) 2000-10-09 2011-07-15 Isis Innovation Therapeutische und toleranz-induzierende antikörper
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
US8809504B2 (en) 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
SI1629011T1 (sl) 2003-05-31 2010-05-31 Micromet Ag Humane molekule za vezavo anti hu cd
DE602004023956D1 (de) 2003-08-18 2009-12-17 Univ California Polypeptid-display-bibliotheken und verfahren zur herstellung und verwendung davon
DE602004030811D1 (de) 2003-10-16 2011-02-10 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
AU2006232310B9 (en) 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
EP2535346B1 (en) 2005-08-31 2017-08-02 The Regents of The University of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
AR057807A1 (es) 2005-09-12 2007-12-19 Novimmune Sa Formulaciones de anticuerpo anti-cd3
JP2009529522A (ja) 2006-03-10 2009-08-20 ディアト 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤
KR101516823B1 (ko) 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 안정화된 폴리펩티드 조성물
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
BRPI0713421A2 (pt) 2006-06-14 2012-03-13 Imclone Systems Incorporated Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero
RS53008B2 (sr) * 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
WO2008119565A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific binding domain
WO2008119566A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
US8293685B2 (en) 2007-07-26 2012-10-23 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
CA2697032C (en) 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
FR2920686B1 (fr) 2007-09-12 2010-01-15 Aldebaran Robotics Robot apte a echanger des programmes informatiques codant pour des comportements
CA2738568C (en) 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
CN105218673A (zh) 2008-10-10 2016-01-06 新兴产品开发西雅图有限公司 Tcr复合物免疫治疗剂
EP2356131A4 (en) 2008-12-08 2012-09-12 Tegopharm Corp MASKING LIGANDS FOR REVERSIBLE INHIBITION OF VERSATILE COMPOUNDS
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
EP3912643B8 (en) 2009-02-13 2023-08-23 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
JP5861223B2 (ja) 2009-02-23 2016-02-16 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. プロタンパク質およびその使用方法
EP2412808B1 (en) 2009-03-25 2016-09-07 Tohoku University Lh-type bispecific antibody
NZ596711A (en) 2009-05-01 2013-11-29 Dual variable domain immunoglobulins and uses thereof
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
CA3083324A1 (en) 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
TWI653333B (zh) * 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
MX340556B (es) 2010-08-24 2016-07-14 Roche Glycart Ag Anticuerpos biespecificos activables.
US9249217B2 (en) 2010-12-03 2016-02-02 Secretary, DHHS Bispecific EGFRvIII x CD3 antibody engaging molecules
TWI588156B (zh) 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
DK2714733T3 (da) 2011-05-21 2019-05-06 Macrogenics Inc Cd3-bindende molekyler, der er i stand til at binde til human og ikke-human cd3
MY169358A (en) 2011-08-23 2019-03-26 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
WO2013026835A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Fc-free antibodies comprising two fab fragments and methods of use
BR112014004168A2 (pt) * 2011-08-23 2017-12-12 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
LT2794658T (lt) 2011-12-19 2017-05-10 Synimmune Gmbh Bispecifinė antikūno molekulė
CA2861031C (en) 2012-02-03 2022-10-25 Carole BOURQUIN Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine
SG10201608307WA (en) 2012-04-20 2016-11-29 Emergent Product Dev Seattle Cd3 binding polypeptides
CN104540518A (zh) 2012-04-27 2015-04-22 西托姆克斯治疗公司 结合表皮生长因子受体的可活化的抗体其使用方法
EP2892924B1 (en) 2012-06-14 2020-11-25 Therapix Biosciences Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
EP2895203A4 (en) 2012-06-15 2016-09-28 Imaginab Inc ANTIGENBINDING CONSTRUCTS FOR CD3
MX2014016038A (es) 2012-06-22 2015-08-14 Cytomx Therapeutics Inc Anticuerpos de reaccion cruzada anti - jagged 1 / jagged 2, anticuerpos anti - jagged activables y metodos para uso de los mismos.
WO2014012085A2 (en) * 2012-07-13 2014-01-16 Zymeworks Inc. Bispecific asymmetric heterodimers comprising anti-cd3 constructs
US9487590B2 (en) 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
CN104271602B (zh) 2012-11-21 2020-08-21 武汉友芝友生物制药有限公司 双特异性抗体
CA2896282C (en) 2013-01-04 2021-07-20 Cytomx Therapeutics, Inc. Compositions and methods for detecting protease activity in biological systems
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
CA2898100C (en) 2013-01-14 2023-10-10 Xencor, Inc. Novel heterodimeric proteins
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US9517276B2 (en) 2013-06-04 2016-12-13 Cytomx Therapeutics, Inc. Compositions and methods for conjugating activatable antibodies
MX373245B (es) 2013-07-05 2020-05-11 Genmab As Anticuerpos cd3 humanizados o quiméricos.
CN105722859B (zh) 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
WO2015066279A2 (en) 2013-10-30 2015-05-07 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
IL270562B (en) 2014-01-31 2022-08-01 Cytomx Therapeutics Inc Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses
JP7020909B2 (ja) 2014-07-25 2022-02-16 シトムクス セラピューティクス，インコーポレイティド 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
BR112017023862A2 (pt) 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
CA3287794A1 (en) 2017-10-14 2025-10-27 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009511521A (ja) 2005-10-11 2009-03-19 ミクロメット・アクチェンゲゼルシャフト 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
JP2010524435A (ja) 2007-04-03 2010-07-22 マイクロメット アーゲー 種間特異的二重特異性バインダー
JP2012504403A (ja) 2008-10-01 2012-02-23 マイクロメット アーゲー 異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体
JP2012514982A (ja) 2009-01-12 2012-07-05 サイトムエックス セラピューティクス，エルエルシー 改変した抗体組成物、それを作製および使用する方法
WO2013128194A1 (en) 2012-02-28 2013-09-06 The University Of Birmingham Immunotherapeutic molecules and uses
WO2013192546A1 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
WO2014047231A1 (en) 2012-09-21 2014-03-27 Regeneron Pharmaceuticals, Inc. Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12060654B2 (en) 2016-11-28 2024-08-13 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
US12195528B2 (en) 2017-11-28 2025-01-14 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand-binding activity
US12077577B2 (en) 2018-05-30 2024-09-03 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising aggrecan binding domain and carrying moiety

Also Published As

Publication number Publication date
BR112017001579A2 (pt) 2017-11-21
US10669337B2 (en) 2020-06-02
WO2016014974A2 (en) 2016-01-28
JP2021087429A (ja) 2021-06-10
AU2015292406A1 (en) 2017-02-09
US20210047406A1 (en) 2021-02-18
EP3172235A2 (en) 2017-05-31
US20240084010A1 (en) 2024-03-14
CA2955947A1 (en) 2016-01-28
AU2021203876A1 (en) 2021-07-08
WO2016014974A3 (en) 2016-03-17
CN107108738A (zh) 2017-08-29
JP2025000814A (ja) 2025-01-07
US20160194399A1 (en) 2016-07-07
JP7564853B2 (ja) 2024-10-09
US11802158B2 (en) 2023-10-31
JP2017523176A (ja) 2017-08-17
AU2015292406B2 (en) 2021-03-11
JP2022191494A (ja) 2022-12-27
JP7168702B2 (ja) 2022-11-09

Similar Documents

Publication Publication Date Title
JP7020909B2 (ja) 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
JP7036860B2 (ja) 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
US11174316B2 (en) Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
AU2018231127A1 (en) CD147 antibodies, activatable CD147 antibodies, and methods of making and use thereof
CN115368457A (zh) 抗tigit抗体及其用途
HK40000977B (en) Multispecific antibodies, multispecific activatable antibodies and methods of using the same
HK40000977A (en) Multispecific antibodies, multispecific activatable antibodies and methods of using the same
EA039736B1 (ru) Анти-pdl1-антитела, активируемые анти-pdl1-антитела и способы их применения
HK1224687A1 (en) Multispecific antibodies, multispecific activatable antibodies and methods of using the same
HK1224687B (en) Multispecific antibodies, multispecific activatable antibodies and methods of using the same
NZ736142B2 (en) Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220203

R150 Certificate of patent or registration of utility model

Ref document number: 7020909

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250